Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research is still not moving fast enough. One area stands out: neurology.
Throughout my career analyzing healthcare data workflows, I have seen brilliant scientific advances slow down at the same frustrating bottleneck: patient recruitment. In neurology, the challenge is not simply finding patients. It is finding the right patients, at the right disease stage, with the right clinical evidence to support eligibility.
This delay is not just an operational inconvenience. It affects patients and families waiting for treatments in diseases where time can mean memory, mobility, independence and quality of life. For progressive neurological conditions, every month lost in recruitment can mean a narrower window for meaningful intervention.
De-Siloing Neurological Data to Accelerate Research
The root cause of this recruitment challenge lies in the fragmented nature of neurological data and the long journey many patients navigate before receiving an accurate diagnosis. Unlike conditions with a single clear lab value or biomarker, neurological diseases often present through overlapping symptoms, subtle progression patterns and years of clinical observations documented across different systems.
A patient’s eligibility for a neurology trial may depend on a combination of physician notes, imaging findings, cognitive scores, medication history, lab results, genetic testing, comorbidities and longitudinal changes over time. Much of this information is not stored neatly in structured fields. It is buried in unstructured notes, radiology reports, scanned documents and disconnected care histories.
The economic impact is also significant. Studies have estimated that clinical trial delays can cost sponsors hundreds of thousands to several million dollars per day, depending on the therapy area, trial phase and commercial assumptions. But in neurology, the human cost is often even more urgent. Many neurological diseases are progressive, and delayed recruitment can mean patients miss the stage at which an investigational therapy may be most appropriate.
Why General-Purpose AI Often Falls Short in Neurology
As pharmaceutical companies began applying artificial intelligence to clinical trial recruitment, many first looked to broad healthcare AI systems trained across general medical datasets. These tools can be useful for operational efficiency, basic chart review and large-scale data search. But neurology presents a different level of complexity.
The brain is not a single-organ workflow with simple rules. Neurological disease progression is often nonlinear. Symptoms can overlap across multiple diagnoses. Eligibility may depend on nuanced clinical context, such as whether cognitive decline is mild or moderate, whether MRI findings suggest a specific disease pattern, whether a seizure history is controlled, or whether a patient’s treatment history indicates progression despite therapy.
This is where purpose-built AI becomes important. A general model may identify a diagnosis code. A neurology-specific model needs to understand the story behind that diagnosis: how the disease evolved, what evidence supports it, what remains uncertain, and whether the patient truly matches the protocol criteria.
The difference lies in data architecture and clinical training. Neurology-focused AI must be able to synthesize multimodal data: unstructured clinical notes, MRI and PET reports, EEG findings, genetic testing, treatment history, cognitive assessments and longitudinal outcomes. Without this depth, AI risks producing false positives that waste site time, or false negatives that miss eligible patients entirely.
In internal benchmarking by NeuroDiscovery AI on defined neurology clinical tasks, neurology-specific models achieved 94.5% accuracy, compared with approximately 70–72% for broader models tested against the same task set. While this is not intended as a universal industry benchmark, it illustrates a larger point: specialization matters when the clinical context is complex.
Solving for Accuracy, Traceability and Trust
Accuracy alone is not enough in clinical research. AI systems used in trial recruitment and real-world evidence also need to be traceable. Every extracted signal should be linked back to the source record, timestamp and clinical context that supports it.
This is especially important because general-purpose AI systems can generate plausible-sounding but incorrect information, often referred to as hallucination. In healthcare, that is not a minor technical issue. For clinical development, it can compromise patient identification, protocol matching, evidence generation and regulatory confidence.
Purpose-built neurology AI platforms are beginning to address this through multi-step validation architectures. Rather than relying on a single model output, these systems can use multiple specialized agents for extraction, validation, reasoning and correction. One layer may identify a clinical signal from a note. Another may validate it against imaging, medication history or longitudinal records. A separate reasoning layer may assess whether the evidence supports trial eligibility. If contradictions appear, the system can flag the case for review or reprocess the evidence.
This kind of closed-loop approach is essential in neurology because trial eligibility is rarely based on one data point. It is based on the relationship between many data points over time.
For sponsors, this creates a stronger evidence trail. For sites, it reduces manual burden. For patients, it increases the chance that they are identified when they are still appropriate for a study.
Real-World Impact on Clinical Development
When neurological data is successfully de-siloed, the impact can be significant. Clinical teams can move from manual chart review and fragmented site outreach to more continuous, evidence-driven recruitment. Instead of asking each site to search from scratch, sponsors can begin with a clearer view of where eligible patients are likely to be, what evidence supports their eligibility and which providers are already caring for them.
This does not replace clinical judgment. It strengthens it. Physicians and research teams still make the final decisions. The role of AI is to surface the right evidence faster, reduce avoidable manual work and help clinical teams focus their time on patients who are more likely to be appropriate for a study.
For neurology, this is particularly important because many trials fail not because the science is weak, but because eligible patients are hard to find, difficult to classify or disconnected from research pathways. Purpose-built AI can help close that gap by connecting longitudinal real-world data with trial execution workflows.
How Pharma Is Rethinking Neurology Trial Development
What we are witnessing is a shift in how pharmaceutical companies approach clinical development in neurology. The traditional model, sequential, fragmented and dependent on manual chart review, is giving way to a more integrated approach. Trial feasibility, cohort identification, site selection and patient matching are increasingly being viewed as connected parts of the same evidence infrastructure.
Forward-thinking pharma companies are no longer treating AI as a downstream recruitment tool. They are beginning to see specialized AI as clinical development infrastructure that should be considered earlier, from protocol design through enrollment planning and real-world evidence generation.
This shift matters because neurological diseases are often progressive and irreversible. Time is not only a cost variable. It is a clinical variable. For patients, faster recruitment can mean earlier access to research options. For sponsors, it can mean better trial execution. For the field, it can mean a shorter path from scientific discovery to clinical impact.
The Path Forward
As we recognize International Clinical Trials Day, the lesson for neurology is clear: clinical research needs speed, but it also needs specificity. General-purpose tools may help organize information, but neurology requires systems that understand disease progression, multimodal evidence and the realities of provider workflows.
Purpose-built AI is not about replacing researchers, clinicians or trial teams. It is about giving them better infrastructure for one of the hardest parts of clinical development: identifying the right patients with the right evidence at the right time.
The future of neurology trials will not be built on broader data alone. It will be built on deeper, more connected and more clinically precise data. If we want breakthrough neurological therapies to reach patients faster, the industry must move beyond generic AI and invest in systems designed for the complexity of the brain.
Authored by: Vamsi Chandra Kasivajjala, Founder and CEO of NeuroDiscovery AI, a company developing AI infrastructure for neurology research and clinical development.
